Bobo Donald E Jr's Form 4 filing
Edwards Lifesciences Corp (EW) · filed May 8, 2023
- Accession no.
- 0001225208-23-005593
- Filed
- May 8, 2023
- Trade date
- May 5-8, 2023
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $499.4K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bobo Donald E JrCIK 0001196661 | Officer (CVP,Strategy/Corp Development) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 5, 2023 | Common Stock | SSaleDisposed | −5,635 | $88.63 | −$499,430.05 | 56,224.69 | Direct | |
| May 7, 2023 | Common Stock | MOption exerciseAcquired | +4,767 | $0.00F1 | $0 | 60,991.69 | Direct | |
| May 7, 2023 | Common Stock | FTax withholdingDisposed | −2,968 | $88.74 | −$263,380.32 | 58,023.69 | Direct | |
| May 8, 2023 | Common Stock | FTax withholdingDisposed | −1,399 | $88.74 | −$124,147.26 | 56,624.69 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 7, 2023 | Common Stock | MOption exerciseDisposed | −4,767 | $0.00 | $0 | 1,308 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4.
Referenced by the price of 1 transaction in Table I.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.